Clinical Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt.
Pharmacology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
Drug Des Devel Ther. 2022 May 30;16:1595-1604. doi: 10.2147/DDDT.S365646. eCollection 2022.
Imatinib is used to treat chronic myelogenous leukemia (CML). Variations in imatinib pharmacokinetics have been linked to genetic variations. That has an impact on imatinib response and adverse effects. Therefore, the aim of the study was to study bone pain as an adverse effect that occurs with imatinib and to investigate the risk factors for bone pain.
The relationship between the peak and trough plasma concentrations of imatinib with bone pain as one of the most frequently occurring adverse effects was examined. Multiple linear regression analysis and binary logistic regression analysis were used to measure the impact of various patients' characteristics on both peak and trough imatinib concentrations and the risk of the occurrence of imatinib-induced bone pain.
As a side effect of imatinib, approximately 15% of patients with CML who were taking it experienced bone pain. This side effect was linked to the imatinib peak and trough plasma levels. Imatinib trough concentration was also linked to gender and the gene SLCO1B3-334T > G (TT). There were significant associations between peak concentrations and gender as well as patient weight.
Higher peak and trough plasma concentrations of imatinib are linked with the risk of the occurrence of bone pain as a side effect of imatinib. Monitoring plasma concentrations of imatinib is useful to predict the bone pain of imatinib and to support quality of life in patients with CML.
伊马替尼用于治疗慢性髓性白血病（CML）。伊马替尼药代动力学的变化与遗传变异有关。这会影响伊马替尼的反应和不良反应。因此，本研究旨在研究骨痛作为伊马替尼发生的不良反应，并探讨其发生的危险因素。
研究了伊马替尼的峰浓度和谷浓度与骨痛之间的关系，骨痛是最常发生的不良反应之一。采用多元线性回归分析和二项逻辑回归分析来衡量各种患者特征对伊马替尼峰浓度和谷浓度以及伊马替尼引起的骨痛发生风险的影响。
约 15%接受伊马替尼治疗的 CML 患者出现了这种药物的副作用，即骨痛。这种副作用与伊马替尼的峰和谷血浆水平有关。伊马替尼谷浓度还与性别和 SLCO1B3-334T > G（TT）基因有关。峰浓度与性别以及患者体重之间存在显著相关性。
伊马替尼的峰浓度和谷浓度越高，发生伊马替尼骨痛不良反应的风险就越大。监测伊马替尼的血浆浓度有助于预测伊马替尼引起的骨痛，并支持 CML 患者的生活质量。
